Our aim was to define the spectrum of urological care for benign prostatic hyperplasia (BPH) and clinically localized prostate cancer.
In 1995 a random sample of 394 American urologists was surveyed with a response rate of 67%. Results : Respondents reported seeing a median of 240 BPH patients during the preceding 12 months, and they had prescribed alpha-blockers for 70 and finasteride for 15.
They had performed a median of 25 transurethral prostatectomies but few other operations for BPH.
Almost all urologists routinely used digital rectal examinations and prostate specific antigen tests for BPH diagnosis.
The next most common studies were American Urological Association symptom scores and uroflowmetry.
Pressure-flow studies were rarely done.
Respondents reported seeing a median of 35 new patients with prostate cancer during the last year, and performing a median of 90 prostate biopsies and 13 radical prostatectomies.
Respondents had referred a median of 10 patients for external beam radiotherapy but few patients received brachytherapy or cryotherapy.
Urologist staging practices varied considerably.
These data provide a picture of current practice regarding the management of BPH and prostate cancer.
Mots-clés Pascal : Hypertrophie, Prostate, Bénin, Afrique, Adénocarcinome, Incidence, Diagnostic, Traitement, Chimiothérapie, Prostatectomie, Radiothérapie, Epidémiologie, Homme, Etats Unis, Amérique du Nord, Amérique, Appareil urinaire pathologie, Prostate pathologie, Appareil génital mâle pathologie, Tumeur maligne, Chirurgie
Mots-clés Pascal anglais : Hypertrophy, Prostate, Benin, Africa, Adenocarcinoma, Incidence, Diagnosis, Treatment, Chemotherapy, Prostatectomy, Radiotherapy, Epidemiology, Human, United States, North America, America, Urinary system disease, Prostate disease, Male genital diseases, Malignant tumor, Surgery
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0408067
Code Inist : 002B14D02. Création : 19/12/1997.